Report Summary Therapeutic advancements have been taking place at a steady pace for oncology treatments. Ensuring that these advancements reach the right patients in a timely and equitable manner across countries is critical for the management of these health conditions. The availability and use of these therapies vary across different countries, however, which can lead to inequities in patient outcomes. While oncology as a whole receives attention in discussions on patient access, trends in hematological malignancy access remain less understood. This report aims to quantify the trends regarding the availability of therapies for hematological malignancies across selected countries with reported oncology therapy access challenges and disparities. Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs indicated in hematological malignancies.